Page last updated: 2024-10-18

glycerol and Neoplasms

glycerol has been researched along with Neoplasms in 120 studies

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."5.39Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013)
"Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion."5.31Prospects for glycerol-rescued hypoglycemia as a cancer therapy. ( McCarty, MF, 2001)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."4.40Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
"A metabolic defect has been observed in extracts of lipomata in which citrate fails to inhibit the conversion of glucose-6-phosphate to glyceride-glycerol."3.65Regulatory defect of glycolysis in human lipoma. ( Atkinson, JN; Galton, DJ; Gilbert, C, 1974)
" The corresponding median values for the apparent bioavailability of oral Genetaxyl were similar when compared with i."2.73Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ( Chen, JS; Chen, PM; Chu, Z; Figg, WD; Gardner, ER; Liau, CT; Lin, YC; Sparreboom, A; Wang, HM; Yang, MH, 2008)
"Twenty-seven adults with cancer pain were prospectively selected according to their primary lesions and problems, but their allocation to study groups was randomized."2.67Prolongation of epidural bupivacaine analgesia with glycerin. ( King, H; Wooten, DJ; Xiao, CS, 1993)
" However, the use of paclitaxel is seriously limited (its bioavailability is <10%) due to several long-standing challenges: its poor water solubility (0."2.61Basic principles of drug delivery systems - the case of paclitaxel. ( Aserin, A; Ezrahi, S; Garti, N, 2019)
"In addition to effective cancer therapies like chemotherapy, radiotherapy and surgery, treatment based on traditional Chinese medicine (TCM) and combined TCM with western medicine has gradually gained attention in Oriental countries."2.61Potential of Fatty Oils from Traditional Chinese Medicine in Cancer Therapy: A Review for Phytochemical, Pharmacological and Clinical Studies. ( Feng, Y; Hong, Y; Huang, Y; Lin, X; Shen, L; Zhu, J, 2019)
"The taxanes' interaction with other anticancer drugs have been extensively investigated in in vitro and in animal models as well as in humans due to the outstanding antitumor activity in a broad range of malignancies."2.41Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. ( Gianni, L; Grasselli, G; Locatelli, A; Vigano, L, 2001)
"A mouse model of cancer cachexia was established where cancer exosomes were injected intravenously."1.91Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss. ( Li, C; Li, Z; Sun, K; Sun, S; Wang, Z; Yao, F, 2023)
"The existence of cancer stem cells (CSCs) poses a major obstacle for the success of current cancer therapies, especially the fact that non-CSCs can spontaneously turn into CSCs, which lead to the failure of the treatment and tumor relapse."1.62Retinoic Acid-Loaded Dendritic Polyglycerol-Conjugated Gold Nanostars for Targeted Photothermal Therapy in Breast Cancer Stem Cells. ( Haag, R; Li, W; Liu, C; Ma, X; Pan, Y; Parshad, B; Schwerdtle, T; Wu, A; Xing, J; Zhou, S, 2021)
"For the combined therapy to breast cancer MCF-7 tumor, the co-delivery system of PCL-HPG-PEI600/DOX/pMMP-9 resulted in a much better inhibition effect on MCF-7 cell proliferation and migration in vitro as well as the suppression effect on MCF-7 tumors in vivo compared to those of single DOX or pMMP-9 formulation used."1.48Construction of a High-Efficiency Drug and Gene Co-Delivery System for Cancer Therapy from a pH-Sensitive Supramolecular Inclusion between Oligoethylenimine- graft-β-cyclodextrin and Hyperbranched Polyglycerol Derivative. ( Kirk, TB; Ma, D; Wu, J; Xu, J; Xu, L; Xue, W; Zhou, X, 2018)
"Subsequently, the anticancer agent doxorubicin (DOX) was loaded through acid-labile hydrazone linkage to yield dND-PG-DOX and dND-PG-RGD-DOX."1.40Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells. ( Abe, S; Akasaka, T; Chen, X; Komatsu, N; Watari, F; Xu, YH; Zhao, L, 2014)
"Since agAQPs are involved in cancer proliferation and malignancy, it might be possible to utilize them as new targets for cancer molecular imaging."1.39Molecular imaging of aquaglycero-aquaporins: its potential for cancer characterization. ( Furukawa, T; Obata, T; Saga, T; Saito, Y, 2013)
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."1.39Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013)
"The dose-dependent targeting and anticancer effect of the MNP-g-HPG-MTX nanoparticles were evaluated, and the results showed that depending on the amount of conjugated MTX and the concentration of the incubated nanoparticles, the uptake of MNP-g-HPG-MTX nanoparticles by human head and neck cancer (KB) cells can be eight times or more higher than those by 3T3 fibroblasts and RAW macrophages."1.39Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe₃O₄ magnetic nanoparticles for targeted anticancer effects. ( Kang, ET; Li, M; Neoh, KG; Tan, JY; Wang, R; Zong, BY, 2013)
"Xenograft studies of breast cancer revealed that the anti-tumor efficacy of PTX-NSP was equal to that of PTX-CrEL-D in tumors originating from both MDA-MB-435 and ZR-75-1 cancer lines."1.38Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. ( Bushman, J; Garbuzenko, OB; Gounder, MK; Kohn, J; Minko, T; Sheihet, L, 2012)
"Paclitaxel is a potent anti-cancer drug that has exhibited clinical activity against several tumours."1.38Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. ( Chen, X; Liu, X; Scott, H; Sun, J; Wang, S; Zhang, Q; Zhang, X, 2012)
"In recent years, the number of cancer patients and their families desiring palliative home-based care in Japan has increased."1.38[Usefulness of subarachnoid phenol-glycerin block therapy for enabling cancer patients with refractory anal pain to proceed to home-based care]. ( Hayashi, S; Inoue, D; Kawakubo, T; Moriya, K; Sakuyama, T; Tanifuji, Y, 2012)
"Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass."1.37Adipose triglyceride lipase contributes to cancer-associated cachexia. ( Das, SK; Diwoky, C; Eder, S; Gorkiewicz, G; Guertl, B; Haemmerle, G; Hoefler, G; Kumari, P; Schauer, S; Tamilarasan, KP; Temmel, H; Trauner, M; Vesely, P; Zechner, R; Zimmermann, R, 2011)
"The 3PNET has been applied to two anticancer drugs, paclitaxel (PTX) and camptothecin (CPT), using Pluronic F127 (F127) polymer as a single excipient."1.36Targeted cancer therapy with novel high drug-loading nanocrystals. ( Bathula, SR; Conwell, C; Huang, L; Liu, F; Liu, Y; Park, JY; Zhang, Y, 2010)
" Benchmark dose analysis of the dose-response data for renal tubular hyperplasia in male and female rats exposed to 3-MCPD in drinking water for 2 years was conducted."1.35Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology. ( Hwang, M; Jang, DD; Kim, J; Yoo, TM; Yoon, E, 2009)
"The purpose of this study was to develop a population pharmacokinetic model for Cremophor EL used as a formulation vehicle for paclitaxel."1.31A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ( Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002)
"Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion."1.31Prospects for glycerol-rescued hypoglycemia as a cancer therapy. ( McCarty, MF, 2001)
" Clinically relevant peripheral neurotoxicity tended to occur at around 1500 mg/m2 cumulative dosage at weekly doses > or =110 mg/m2."1.31Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. ( Briasoulis, E; Haidou, C; Karavasilis, V; Pavlidis, N; Piperidou, C; Tzamakou, E, 2002)
"Fifteen adult patients with cancer pain received 0."1.28[Epidural administration of bupivacaine in glycerine solution can prolong analgesia]. ( King, HK; Wooten, DJ; Xiao, CS, 1992)
"Eight malnourished cancer and 10 non-cancer patients (11% weight loss) were compared to seven well-nourished and weight-stable patients."1.28Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. ( Drott, C; Lundholm, K; Persson, H, 1989)
"Compared with control patients, cancer patients had a higher excretion of cortisol, adrenaline, and noradrenaline, although noradrenaline excretion reached statistical significance only when normalized to creatinine excretion."1.27Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. ( Drott, C; Lundholm, K; Svaninger, G, 1988)
"While malnutrition attending cancer cachexia may be associated with variable losses of body fat, lipid metabolism has been only minimally studied."1.27Cancer cachexia and the rate of whole body lipolysis in man. ( Brennan, MF; Horowitz, GD; Jeevanandam, M; Lowry, SF, 1986)
"The turnover rate of glucose in the cancer patients correlated inversely to their body weight index."1.26Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. ( Edström, S; Ekman, L; Karlberg, I; Lundholm, K; Scherstén, T, 1982)
"The finding that 2 uterine cancers contained 70 S RNA and reverse transcriptase indicates that uterine cancers may belong to the list of malignancies where the involvement of oncornaviruses is suspected."1.26Oncornaviruslike particles in human malignancies. ( Dörfler, W; Laufs, R; Steinke, H, 1976)

Research

Studies (120)

TimeframeStudies, this research(%)All Research%
pre-199035 (29.17)18.7374
1990's11 (9.17)18.2507
2000's19 (15.83)29.6817
2010's41 (34.17)24.3611
2020's14 (11.67)2.80

Authors

AuthorsStudies
Umezawa, F1
Natsume, M1
Fukusada, S1
Nakajima, K1
Yamasaki, F1
Kawashima, H1
Kuo, CW1
Khoo, KH1
Shimura, T1
Yagi, H1
Kato, K1
Wang, R3
Wang, X5
Zhao, J1
Jin, J1
Fan, W1
Zhu, X2
Chen, Q2
Zhang, B2
Lan, L1
Qu, K1
Zhu, L2
Wang, J8
Komatsu, N5
Sun, S2
Wang, Z3
Yao, F1
Sun, K1
Li, Z3
Li, C3
Nishikawa, M2
Yu, J2
Kang, HG2
Suzuki, M1
Simón, M2
Norregaard, K1
Jørgensen, JT1
Oddershede, LB1
Kjaer, A1
Pant, K1
Neuber, C1
Zarschler, K1
Wodtke, J1
Meister, S1
Haag, R5
Pietzsch, J1
Stephan, H1
Nagel, G1
Sousa-Herves, A1
Wedepohl, S1
Calderón, M1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Huang, L3
Hu, K1
Liu, H4
Wang, H4
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X3
Wang, B4
Zhang, Q5
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W3
Zang, YP2
Niu, LL2
Fu, YJ3
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J3
Jiang, H1
He, C2
Xiao, Z1
Xu, J5
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X7
Xu, N1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W4
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C3
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y7
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y8
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J8
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y9
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L4
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J3
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y4
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J3
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C3
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X7
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X2
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X2
Pang, B1
Liu, Q2
Liu, X5
Huang, Y3
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J2
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M2
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W2
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S2
Luo, M1
Wu, J2
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L2
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D2
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P2
Sun, YH1
Zhang, HB1
Mbous, YP1
Hayyan, M1
Wong, WF1
Hayyan, A1
Looi, CY1
Hashim, MA1
Rahman, M1
Alrobaian, M1
Almalki, WH1
Mahnashi, MH1
Alyami, BA1
Alqarni, AO1
Alqahtani, YS1
Alharbi, KS1
Alghamdi, S1
Panda, SK1
Fransis, A1
Hafeez, A1
Beg, S1
Cherri, M1
Ferraro, M1
Mohammadifar, E1
Quaas, E1
Achazi, K2
Ludwig, K1
Grötzinger, C1
Schirner, M1
Zou, Y2
Cheng, G1
Xu, S1
Zhong, Y1
Nie, C1
Pan, Y2
Adeli, M1
Xing, J1
Zhou, S1
Parshad, B1
Schwerdtle, T1
Wu, A1
El Nemr, S1
Al-Najjar, BY1
Omer, HK1
Elhissi, AMA1
Alhnan, MA1
Chowdhury, MR1
Moshikur, RM1
Wakabayashi, R1
Tahara, Y1
Kamiya, N1
Moniruzzaman, M1
Goto, M1
Aikman, B1
de Almeida, A1
Meier-Menches, SM1
Casini, A1
Leithner, K1
Triebl, A1
Trötzmüller, M1
Hinteregger, B1
Leko, P1
Wieser, BI1
Grasmann, G1
Bertsch, AL1
Züllig, T1
Stacher, E1
Valli, A1
Prassl, R1
Olschewski, A1
Harris, AL1
Köfeler, HC1
Olschewski, H1
Hrzenjak, A1
Kirk, TB2
Ma, D2
Xue, W2
Ezrahi, S1
Aserin, A1
Garti, N1
Wen, Y1
Xu, M1
Sang, H1
Lin, X1
Hong, Y1
Feng, Y1
Shen, L1
Yoshino, F1
Amano, T1
Kimura, F1
Furusho, Y1
Chano, T1
Murakami, T1
Lee, CH1
Rajendran, R1
Jeong, MS1
Ko, HY1
Joo, JY1
Cho, S1
Chang, YW1
Kim, S1
Elmeshad, AN1
Mortazavi, SM1
Mozafari, MR1
Saito, Y1
Furukawa, T1
Obata, T1
Saga, T1
Oh, SJ1
Kim, SH2
Jeong, K1
Park, Y1
Huh, YM1
Son, JH1
Suh, JS1
Mokhtarani, M1
Diaz, GA1
Rhead, W1
Berry, SA1
Lichter-Konecki, U1
Feigenbaum, A1
Schulze, A1
Longo, N1
Bartley, J1
Berquist, W1
Gallagher, R1
Smith, W1
McCandless, SE1
Harding, C1
Rockey, DC1
Vierling, JM1
Mantry, P1
Ghabril, M1
Brown, RS1
Dickinson, K1
Moors, T1
Norris, C1
Coakley, D1
Milikien, DA1
Nagamani, SC1
Lemons, C1
Lee, B1
Scharschmidt, BF1
Xu, YH1
Akasaka, T1
Abe, S1
Watari, F1
Lin, JX1
Fan, ZY1
Lin, Q1
Wu, DH1
Wu, XY1
Chen, YR1
Fang, HY1
Wu, DB1
Wen, JY1
Dong, M1
Ma, XK1
Wan, XB1
Kong, M1
Hou, L1
Feng, C1
Cheng, X1
Misri, R2
Wong, NK1
Shenoi, RA1
Lum, CM1
Chafeeva, I1
Toth, K1
Rustum, Y1
Kizhakkedathu, JN1
Khan, MK1
Jia, HZ1
Wang, XL1
Yang, B2
Chen, WH1
Chen, G1
Zhao, YF1
Zhuo, RX1
Zhang, XZ1
Ebadi, M1
Mazurak, VC1
Zheng, Q1
Wu, JP1
Jia, Y1
Wei, Q1
Chu, Z1
Chen, JS1
Liau, CT1
Wang, HM1
Lin, YC1
Yang, MH1
Chen, PM1
Gardner, ER1
Figg, WD1
Sparreboom, A5
Cho, WS1
Han, BS1
Nam, KT1
Park, K1
Jeong, J1
Jang, DD2
Danhier, F1
Lecouturier, N1
Vroman, B1
Jérôme, C1
Marchand-Brynaert, J1
Feron, O1
Préat, V1
Han, M1
He, CX1
Fang, QL1
Yang, XC1
Diao, YY1
Xu, DH1
He, QJ1
Hu, YZ1
Liang, WQ1
Gao, JQ1
Hwang, M1
Yoon, E1
Kim, J1
Yoo, TM1
Koyyalagunta, D1
Burton, AW1
Liu, F1
Park, JY1
Conwell, C1
Bathula, SR1
Deniau, AL1
Mosset, P1
Pédrono, F1
Mitre, R1
Le Bot, D1
Legrand, AB1
Iannitti, T1
Palmieri, B1
AYRE, JE1
DAKIN, E1
Das, SK1
Eder, S1
Schauer, S1
Diwoky, C1
Temmel, H1
Guertl, B1
Gorkiewicz, G1
Tamilarasan, KP1
Kumari, P1
Trauner, M1
Zimmermann, R1
Vesely, P1
Haemmerle, G1
Zechner, R1
Hoefler, G1
Rydén, M1
Agustsson, T1
Andersson, J1
Bolinder, J1
Toft, E1
Arner, P1
Sheihet, L1
Garbuzenko, OB1
Bushman, J1
Gounder, MK1
Minko, T1
Kohn, J1
Saatchi, K1
Soema, P1
Gelder, N1
McPhee, K1
Baker, JH1
Reinsberg, SA1
Brooks, DE1
Häfeli, UO1
Wang, S1
Scott, H1
García-Díaz, M1
Kawakubo, M1
Mroz, P1
Sagristà, ML1
Mora, M1
Nonell, S1
Hamblin, MR2
Huang, YY1
Balasubramanian, T1
Yang, E1
Luo, D1
Diers, JR1
Bocian, DF1
Lindsey, JS1
Holten, D1
Li, M1
Neoh, KG1
Zong, BY1
Tan, JY1
Kang, ET1
Hayashi, S1
Inoue, D1
Sakuyama, T1
Tanifuji, Y1
Moriya, K1
Kawakubo, T1
Verkman, AS1
van den Bongard, HJ1
Mathôt, RA1
van Tellingen, O2
Schellens, JH2
Beijnen, JH2
Titov, VN1
Lisitsyn, DM1
Burns, J1
Stephens, M1
GRAHAM, OL2
KIT, S2
WOOD, HG1
JOFFE, S1
GILLESPIE, R1
HANSEN, RG1
HARDENBROOK, H1
WOERNLEY, DL1
CARRUTHERS, C1
LILGA, KT1
BAUMLER, A1
STIRPE, M1
BUCCI, MG1
FALUDI, B1
D ANIEL, AF1
GYURJAN, I1
ANDA, S1
BRUECKNER, L1
WOOLFREY, BF1
MAHER, RM1
PAPO, I1
SMITH, MC1
LYCETTE, RM1
LESLIE, RB1
MARKUS, B2
Loi, S1
Rischin, D2
Michael, M1
Yuen, K1
Stokes, KH2
Ellis, AG1
Millward, MJ2
Webster, LK2
Ishiguro, K1
Shyam, K1
Penketh, PG1
Sartorelli, AC1
Zahr, AS1
Pishko, MV1
Perrault, R1
Jackson, JR1
Martin-Villar, J1
Smiley, RK1
Bennegård, K1
Edén, E1
Ekman, L2
Scherstén, T2
Lundholm, K4
Allen, ED1
Gau, TC1
Natale, RB1
Edström, S1
Karlberg, I1
Nygren, P1
Csoka, K1
Jonsson, B1
Fridborg, H1
Bergh, J1
Hagberg, H1
Glimelius, B1
Brodin, O1
Tholander, B1
Kreuger, A1
Hyytinen, E1
Visakorpi, T1
Kallioniemi, A1
Kallioniemi, OP1
Isola, JJ1
King, H1
Xiao, CS2
Wooten, DJ2
Giercksky, KE1
Watanabe, N1
Sato, Y1
Yamauchi, N1
Niitsu, Y1
Newton, H1
Fisher, J1
Arnold, JR1
Pegg, DE1
Faddy, MJ1
Gosden, RG1
Lokich, J1
Anderson, N1
Verweij, J4
van der Burg, ME1
Loos, WJ2
Brouwer, E2
Viganò, L2
Locatelli, A2
de Vos, AI1
Nooter, K1
Stoter, G1
Gianni, L3
Toner, GC1
Bishop, JF1
Olver, IN1
Linahan, BM1
Linsenmeyer, ME1
Woodcock, DM1
van Zuylen, L2
Mross, K2
McCarty, MF1
Grasselli, G1
Kirita, T1
Ohnishi, K1
Ohnishi, T1
Malingré, MM1
Ouwehand, M1
Bardelmeijer, HA1
Rosing, H1
Koopman, FJ1
Schot, ME1
Ten Bokkel Huinink, WW1
Gelderblom, H1
ten Tije, AJ1
Behringer, D1
Mielke, S1
van Zomeren, DM1
Briasoulis, E1
Karavasilis, V1
Tzamakou, E1
Haidou, C1
Piperidou, C1
Pavlidis, N1
Steinke, H1
Laufs, R1
Dörfler, W1
Brechner, VL1
Ferrer-Brechner, T1
Allen, GD1
Snyder, F2
Snyder, C1
King, HK1
Yang, XX1
Drott, C2
Persson, H1
Svaninger, G1
Levinson, MR1
Groeger, JS1
Jeevanandam, M3
Brennan, MF3
Legaspi, A1
Starnes, HF1
Beliaev, DG1
Frid, IA1
Genin, IB1
Horowitz, GD1
Lowry, SF1
Mannheimer, E1
Pavlova, ZV1
Sviridova, SP1
Isakova, ME1
Evans, RJ1
Mackay, IM1
Atkinson, JN1
Galton, DJ1
Gilbert, C1
Stovner, J1
Endresen, R1
Byfield, JE1
Stein, JJ1
Wood, R1
Wenzel, M1
Gibney, E1
Fushing, H1
Vanderwaal, K1
McCowan, B1
Koehl, P1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension[NCT00947544]Phase 217 participants (Actual)Interventional2010-03-31Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy[NCT00999167]Phase 2189 participants (Actual)Interventional2009-12-31Completed
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)[NCT00992459]Phase 346 participants (Actual)Interventional2009-10-31Completed
A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)[NCT00947297]Phase 360 participants (Actual)Interventional2009-11-30Completed
A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)[NCT01347073]Phase 323 participants (Actual)Interventional2011-07-31Completed
A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200]Phase 214 participants (Actual)Interventional2007-10-31Completed
Clinical Study to Evaluate the Effectiveness and Safety of the Consumption of a Food Supplement in a Group of Healthy People[NCT03492086]60 participants (Actual)Interventional2015-08-31Completed
Biochemical and Functional Biomarkers of Cachexia in Cancer Patients[NCT03191955]120 participants (Anticipated)Observational2015-11-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Average Ammonia Values on NaPBA vs. HPN-100 on the Last Day of Treatment With Each Drug (Switch Over)

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionµmol/L (Mean)
HPN-10028.68
NaPBA37.75

Blood Ammonia Control

To evaluate control of blood ammonia by HPN-100 compared with NaPBA in pediatric patients with UCDs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμmol∙h/L (Mean)
HPN-100603.83
NaPBA814.62

NH3 Cmax on NaPBA vs. HPN-100 on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμmol/L (Mean)
HPN-10047.77
NaPBA55.66

Plasma PAA (Phenylacetate) AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg•h/mL AUC 0-24 (Mean)
HPN-100964
NaPBA773

Plasma PAGN AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg*h/mL AUC 0-24 (Mean)
HPN-1001378
NaPBA1015

Plasma PBA (Phenylbutyrate) AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionµg*h/ml AUC 0-24 (Mean)
HPN-100631
NaPBA236

Quality of Life Assessed by the SF-15 Questionnaire

"change from baseline to Month 12.~The SF 15 questionnaire consists of 15 questions that assess the following:~Physical functioning (5 questions)~Emotional functioning (4 questions)~Social functioning (3 questions)~School functioning (3 questions) Items were scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or a 3-point scale (0 [not at all], 2 [sometimes], or 4 [a lot] for the young child self-report). Items were reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score was 0-100 scale (averaged from each functional areas). In the 0-100 scale, 0 is the worst score and 100 is best score.~Improved quality of life was shown by increased total score from baseline to Month 12." (NCT00947544)
Timeframe: 1 year

Interventionscore on a scale (Mean)
HPN-1004.0

Rate (Percentage) of Ammonia Values Above Upper Limit of Normal (ULN) on NaPBA vs. HPN-100

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionpercentage of sample (Number)
HPN-10018.4
NaPBA31.6

Rate of Adverse Events During the Switchover Part of the Study Rate of Adverse Events (Number of Participants Showing Adverse Events)

To evaluate the safety and PK characteristics of HPN-100 compared with sodium phenylbutyrate (NaPBA) in pediatric patients with urea cycle disorders (UCDs) (NCT00947544)
Timeframe: 1 week on each treatment for a total of 2 week.

Interventionparticipants (Number)
HPN-1004
NaPBA2

Urinary PAGN 24-hour Excretion Values on NaPBA vs. HPN-100 (Switch Over)

Urinary PAGN (phenylacetylglutamine) 24-hour excretion. Urine was collect during 0-12 hrs and 12-24 hrs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg (Mean)
HPN-10012501037
NaPBA12512426

Number and Causes of Hyperammonemic Events (Safety Extension)

"Number of Subjects with at Least One Hyperammonemic Crisis.~Hyperammonemic crisis is defined as follows:~• Clinical symptoms associated with ammonia of ≥ 100 µmol/L" (NCT00947544)
Timeframe: 1 year

,
Interventionparticipants (Number)
Number of subjects with at least 1 HACNumber of Crises
Pre-Enrollment (NaPBA)58
Safety Extension (HPN-100)33

Part B: Proportion of Subjects Who Exhibit an HE Episode, Defined as Either of the Following During the Treatment Phase: WH ≥2; WH Grade and Asterixis Grade Increase of 1 Each, if Baseline WH = 0

"An HE event was defined as occurrences of either a West Haven (WH) Grade ≥2 or a WH Grade 1 and asterixis grade increase of 1 (if baseline WH = 0).~The WH criteria are widely used for rating the severity of HE and are summarized below:~Grade 1: trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition Grade 2: lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behavior, impaired performance of subtraction Grade 3: somnolence to semi-stupor but responsive to verbal stimuli, confusion, gross disorientation Grade 4: coma (unresponsive to verbal or noxious stimuli)~Asterixis was assessed after arm and forearm extension along with wrist dorsiflexion for 30 seconds and assigned a grade according to the following criteria:~Grade 1: rare flaps Grade 2: occasional irregular flaps Grade 3: frequent flaps Grade 4: continuous flaps" (NCT00999167)
Timeframe: Part B: 112 Days

Interventionparticipants (Number)
HPN-10019
Placebo32

Time to Meeting the Primary Endpoint

Secondary efficacy endpoint. The time to the first HE episode during the treatment period was calculated using the Kaplan-Meier method. Subjects who did not experience an HE episode were censored at the time of their last asterixis assessment. Subjects who had no post-randomization data for the primary endpoint were considered to have an HE episode at Day 1. (NCT00999167)
Timeframe: 112 Days

InterventionDays (Median)
HPN-100NA
PlaceboNA

Total Number of HE Events

Secondary efficacy endpoint. The total number of HE events during the treatment phase for subjects in the placebo and active arms. (NCT00999167)
Timeframe: 112 Days

InterventionHE event (Number)
HPN-10035
Placebo57

Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

Changes from Baseline to Day 56 and the Final Visit were compared between treatment groups using an ANCOVA model for the total index RBANS score ). The index score is a sum of the scores for each of the 5 individual domains (immediate memory, visuospatial/constructional, language, attention). The minimum and maximum total index scores are 40 and 160, respectively; a higher score is better. (NCT00999167)
Timeframe: Day 56, Final Visit (D112)

,
Interventionunits on a scale (Least Squares Mean)
Change from Baseline to D56 (Total Score)Change from Baseline to Final Visit (Total Score)
HPN-100-0.5-10.7
Placebo3.2-9.7

Part A: The Rate of AEs and Tolerability of HPN-100

Part A: The rate of AEs and tolerability of 6 mL and 9 mL doses of HPN-100 were considered the primary safety endpoints for Part A. Safety assessments included adverse events, laboratory tests (including ammonia, hematology, coagulation, liver function and serum chemistry parameters), vital signs, physical and neurological examinations, and electrocardiograms. (NCT00999167)
Timeframe: Part A: 28 days

InterventionSubjects (Number)
Any AEGastrointestinal disordersMetabolism and nutrition disordersInfection and infestationsNervous system disordersBlood and lymphatic system disordersInjury, poisoning and procedural complicationsMusculoskeletal and connective tissue disordersPsychiatric disordersAny SAEDeath
HPN-100 BID119744222252

Cmax for PAA of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA52.2
HPN-10038.5

Cmax for PBA of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA80.9
HPN-10051.9

Cmax PAGN of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA78.6
HPN-10086.8

Correlation Between Urinary Phenylacetylglutamine (PAGN) Excretion Over 24 Hours (U-PAGN24-hour Excr) and Venous Ammonia - Area Under the Concentration-time Curve From Time 0 (Predose) to 24 Hours (AUC0-24)

The correlation between 24-hour urinary phenylacetylglutamine (PAGN) excretion (U-PAGN24-hour Excr) and venous ammonia AUC0-24 was summarized and the correlation was tested using the Spearman rank-order correlation. (NCT00992459)
Timeframe: 28 Days

Interventioncorrelation coefficient (Number)
NaPBA0.437
HPN-1000.219

Maximum Ammonia Values Observed on NaPBA Versus HPN-100

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionµmol/L (Mean)
NaPBA70.83
HPN-10060.94

Number and Severity of Symptomatic Hyperammonemic Crises

Severity of symptomatic hyperammonemic crises was measured by peak ammonia level (µmol/L) when it is >= 100 µmol/L. (NCT00992459)
Timeframe: 29 Days

Interventionevents (Number)
NaPBA1
HPN-1000

Rate (Percentage) of Ammonia Values Above Upper Limit of Normal (ULN) on NaPBA Versus HPN-100

NaPBA treated arm: total 345 blood samples were collected. HPN-100 treated arm: 343 blood samples were collected. (NCT00992459)
Timeframe: on Day 14 and Day 28

Interventionsamples (Number)
NaPBA125
HPN-100122

Rate of Adverse Events in Each Treatment Group

(NCT00992459)
Timeframe: 29 Days

Interventionparticipants (Number)
NaPBA23
HPN-10027

The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. Arm A day 14 and Arm B day 28 data were combined as a NaPBA treatment Arm. Arm B day 14 and Arm A day 28 data were combined as a HPN-100 treatment Arm. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμmol∙h/L (Mean)
NaPBA976.6
HPN-100865.35

U-PAGN24-hour Excr of NaPBA and HPN-100

(NCT00992459)
Timeframe: 24 hours on Day 14 of each treatments

Interventionμg (Mean)
NaPBA13627515
HPN-10013502745

Number and Causes of Hyperammonemic Events

Number of hyperammonemic crises per patient (NCT00947297)
Timeframe: 1 year

Interventionhyperammonemic events (Mean)
HPN-1000.20

Patient Satisfaction With HPN-100

Drug preference will be noted at week 3 (NCT00947297)
Timeframe: Month 1 post dose

Intervention% preferred HPN-100 (Number)
HPN-10090

Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug)

(NCT00947297)
Timeframe: 1 year

Interventionparticipants (Number)
HPN-10033

Blood Ammonia Levels

Venous Ammonia levels over time (NCT00947297)
Timeframe: 1 Year

InterventionUmol/L (Mean)
BaselineMonth 12
HPN-10027.62324.202

Adverse Events

Rate of adverse events during the Safety Extension portion of the protocol ( please note: HPN-100 treatment only during Safety Extension ) (NCT01347073)
Timeframe: 12 months

Interventionparticipants (Number)
HPN-10023

Adverse Events

Rate of adverse events during the Switch-Over portion of the Protocol (NCT01347073)
Timeframe: 2 weeks

Interventionparticipants (Number)
NaPBA0
HPN-1006

Blood Ammonia

24-hour ammonia AUC of blood ammonia levels on Days 1 (NaPBA) and 10 (HPN-100) were compared. Ammonia was assessed at Hour 0 (pre-first dose, fasted), Hour 8 (~2-4 hours after lunch or the second main meal and dose of NaPBA), Hour 12 (~4 hours after the last main meal) and 24 hours post-first dose (pre-first dose on following day, fasted). (NCT01347073)
Timeframe: 2 weeks

Interventionumol/L*hours (Mean)
NaPBA914.43
HPN-100647.63

Frequency of Ammonia Levels Greater Than the Upper Limit of Normal (ULN) on HPN-100 Compared With NaPBA

Ammonia values were converted to SI units (umol/L) and normalized to a standard ULN of 35 umol/L prior to analysis (NCT01347073)
Timeframe: 2 weeks

InterventionAmmonia Values > ULN (Number)
NaPBA22
HPN-1008

Hyperammonemic Crisis

Rate of HAC during pre-enrollment on NaPBA compared to HAC during HPN-100 treatment (NCT01347073)
Timeframe: 1 year

Interventionnumber of crises (Number)
Pre-enrollment29
Long-term Phase12

Number of Subjects Experienced Adverse Events

(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)

Interventionparticipants (Number)
Buphenyl7
HPN-1005

Number of Subjects Experienced Serious Adverse Events

(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)

Interventionparticipants (Number)
Buphenyl1
HPN-1000

Drug Preference for HPN-100 or Buphenyl® (as Assessed by Global Preference Question)

(NCT00551200)
Timeframe: End of Study

Interventionparticipants (Number)
prefer Buphenylprefer HPN-100
Buphenyl to HPN-10019

Pharmacokinetics (Plasma and Urine PK Parameters of Study Drugs and Their Metabolites)

measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)

,
Interventionμg*h/mL (Mean)
AUC0-24 PBA (phenylbutyrate) in plasmaAUC0-24 PAA (phenylacetate) in plasmaAUC0-24 PAGN (phenylacetylglutamine) in plasma
HPN-100 Steady State5405751098
NaPBA Steady State7405961133

Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve)

Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation

,
Interventionμmol/L (Mean)
in peakin TNAUC (time-normalized area under the curve)
HPN-100 Steady State56.326.5
NaPBA Steady State79.138.4

Reviews

16 reviews available for glycerol and Neoplasms

ArticleYear
Clinical value and molecular mechanism of AQGPs in different tumors.
    Medical oncology (Northwood, London, England), 2022, Aug-16, Volume: 39, Issue:11

    Topics: Aquaglyceroporins; Glycerol; Humans; Hydrogen Peroxide; Neoplasms

2022
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp

2023
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Superbranched polyglycerol nanostructures as drug delivery and theranostics tools for cancer treatment.
    Drug discovery today, 2021, Volume: 26, Issue:4

    Topics: Biocompatible Materials; Drug Carriers; Drug Delivery Systems; Glycerol; Humans; Nanostructures; Neo

2021
Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents.
    Metallomics : integrated biometal science, 2018, 05-23, Volume: 10, Issue:5

    Topics: Animals; Antineoplastic Agents; Aquaporins; Glycerol; Humans; Hydrogen Peroxide; Models, Biological;

2018
Basic principles of drug delivery systems - the case of paclitaxel.
    Advances in colloid and interface science, 2019, Volume: 263

    Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Biological Transport; Drug Delivery Syst

2019
Potential of Fatty Oils from Traditional Chinese Medicine in Cancer Therapy: A Review for Phytochemical, Pharmacological and Clinical Studies.
    The American journal of Chinese medicine, 2019, Volume: 47, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drugs, Chinese Herbal; Fatty Acids; Glycerol; Humans;

2019
Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.
    Mediators of inflammation, 2015, Volume: 2015

    Topics: Adipokines; Adipose Tissue; Biomarkers; Cachexia; Carrier Proteins; Cytokines; Glycerol; Glycoprotei

2015
The role of chemical neurolysis in cancer pain.
    Current pain and headache reports, 2010, Volume: 14, Issue:4

    Topics: Animals; Ethanol; Glycerol; Humans; Neoplasms; Nerve Block; Pain; Pain Management; Phenol

2010
Multiple beneficial health effects of natural alkylglycerols from shark liver oil.
    Marine drugs, 2010, Jul-19, Volume: 8, Issue:7

    Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fish Oils; Glycerol; Humans; Mice;

2010
An update on the therapeutic role of alkylglycerols.
    Marine drugs, 2010, Aug-05, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Clinical Trials as Topic; Fish Oils; Glycerol;

2010
Palliative wound management: the use of a glycerine hydrogel.
    British journal of nursing (Mark Allen Publishing), 2003, Volume: 12, Issue:6 Suppl

    Topics: Adult; Aged; Cryoprotective Agents; Female; Glycerol; Humans; Hydrogels; Male; Neoplasms; Palliative

2003
Role of formulation vehicles in taxane pharmacology.
    Investigational new drugs, 2001, Volume: 19, Issue:2

    Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP

2001
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
    Investigational new drugs, 2001, Volume: 19, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Cisplatin; Docet

2001
A new strategy for cancer therapy based on a predictive indicator.
    Human cell, 2001, Volume: 14, Issue:1

    Topics: Apoptosis; Forecasting; Genes, p53; Genetic Therapy; Genotype; Glycerol; Humans; Molecular Chaperone

2001
Glycerolipids and cancer.
    Progress in biochemical pharmacology, 1975, Volume: 10

    Topics: Animals; Choline; Chromatography, Thin Layer; Dogs; Ethanolamines; Ethers; Glycerides; Glycerol; Hum

1975

Trials

10 trials available for glycerol and Neoplasms

ArticleYear
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp

2023
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
A comparison of dioctahedral smectite and iodine glycerin cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: a pilot study.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015, Volume: 19, Issue:2

    Topics: Administration, Topical; Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Agents; Female; G

2015
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological A

2008
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carboplatin; Cross-Over Stu

2004
Prolongation of epidural bupivacaine analgesia with glycerin.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1993, Volume: 40, Issue:5 Pt 1

    Topics: Aged; Analgesia, Epidural; Bupivacaine; Chronic Disease; Delayed-Action Preparations; Female; Glycer

1993
Phase I trial of cremophor EL with bolus doxorubicin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:10

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Cross-Over Studies; Doxorubicin; Female; Glycerol; Humans;

1998
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    Anti-cancer drugs, 2000, Volume: 11, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Glycerol; Humans; Infusions, Intravenous; Neoplasms; Paclitaxel;

2000
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    British journal of cancer, 2001, Nov-16, Volume: 85, Issue:10

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combin

2001
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Fema

2002

Other Studies

96 other studies available for glycerol and Neoplasms

ArticleYear
Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.
    International journal of molecular sciences, 2022, Jun-15, Volume: 23, Issue:12

    Topics: Dystroglycans; Glycerol; Glycerophosphates; Humans; Neoplasms; Phosphates; Polysaccharides; RNA Nucl

2022
Poly(Glycerol)-Based Biomedical Nanodevices Constructed by Functional Programming on Inorganic Nanoparticles for Cancer Nanomedicine.
    Accounts of chemical research, 2023, 01-17, Volume: 56, Issue:2

    Topics: Glycerol; Humans; Nanomedicine; Nanoparticles; Neoplasms; Polymers

2023
Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss.
    Human molecular genetics, 2023, 06-19, Volume: 32, Issue:13

    Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Animals; Autophagy-Related Proteins; Cachexia; Exo

2023
Rational Design, Multistep Synthesis and in Vitro Evaluation of Poly(glycerol) Functionalized Nanodiamond Conjugated with Boron-10 Cluster and Active Targeting Moiety for Boron Neutron Capture Therapy.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2023, Nov-13, Volume: 29, Issue:63

    Topics: Animals; Boron; Boron Compounds; Boron Neutron Capture Therapy; Glycerol; Mice; Nanodiamonds; Neopla

2023
Fractionated photothermal therapy in a murine tumor model: comparison with single dose.
    International journal of nanomedicine, 2019, Volume: 14

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Radiation; Female; Gl

2019
Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging.
    Small (Weinheim an der Bergstrasse, Germany), 2020, Volume: 16, Issue:7

    Topics: Diagnostic Techniques and Procedures; Endocytosis; ErbB Receptors; Glycerol; Hep G2 Cells; Humans; N

2020
Matrix Metalloproteinase-sensitive Multistage Nanogels Promote Drug Transport in 3D Tumor Model.
    Theranostics, 2020, Volume: 10, Issue:1

    Topics: Cell Survival; Delayed-Action Preparations; Dendrimers; Doxorubicin; Drug Carriers; Drug Liberation;

2020
Simulation of Deep Eutectic Solvents' Interaction with Membranes of Cancer Cells Using COSMO-RS.
    The journal of physical chemistry. B, 2020, 10-15, Volume: 124, Issue:41

    Topics: Choline; Ethylene Glycol; Glycerol; Hydrogen Bonding; Neoplasms; Solvents

2020
Biodegradable Dendritic Polyglycerol Sulfate for the Delivery and Tumor Accumulation of Cytostatic Anticancer Drugs.
    ACS biomaterials science & engineering, 2021, 06-14, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Cytostatic Agents; Glycerol; Humans; Neoplasms; Polymers; Sulfates

2021
Effect of Protein Corona on Mitochondrial Targeting Ability and Cytotoxicity of Triphenylphosphonium Conjugated with Polyglycerol-Functionalized Nanodiamond.
    Molecular pharmaceutics, 2021, 07-05, Volume: 18, Issue:7

    Topics: A549 Cells; Cell Proliferation; Drug Carriers; Glycerol; HeLa Cells; Humans; Mitochondria; Nanodiamo

2021
Co-Delivery of Doxorubicin and Chloroquine by Polyglycerol Functionalized MoS2 Nanosheets for Efficient Multidrug-Resistant Cancer Therapy.
    Macromolecular bioscience, 2021, Volume: 21, Issue:11

    Topics: Chloroquine; Disulfides; Doxorubicin; Drug Resistance, Neoplasm; Glycerol; HeLa Cells; Humans; Micro

2021
Retinoic Acid-Loaded Dendritic Polyglycerol-Conjugated Gold Nanostars for Targeted Photothermal Therapy in Breast Cancer Stem Cells.
    ACS nano, 2021, 09-28, Volume: 15, Issue:9

    Topics: Glycerol; Gold; Neoplasms; Neoplastic Stem Cells; Photothermal Therapy; Polymers; Tretinoin

2021
Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
    Pharmaceutical development and technology, 2018, Volume: 23, Issue:1

    Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Carriers; Glyc

2018
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
    Molecular pharmaceutics, 2018, 06-04, Volume: 15, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Delivery Systems; Drug Hypersensitivity; E

2018
The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2018, 06-12, Volume: 115, Issue:24

    Topics: A549 Cells; Animals; Glucose; Glutamine; Glycerol; Heterografts; Humans; Lactic Acid; Male; Mice; Mi

2018
Construction of a High-Efficiency Drug and Gene Co-Delivery System for Cancer Therapy from a pH-Sensitive Supramolecular Inclusion between Oligoethylenimine- graft-β-cyclodextrin and Hyperbranched Polyglycerol Derivative.
    ACS applied materials & interfaces, 2018, Oct-24, Volume: 10, Issue:42

    Topics: Animals; beta-Cyclodextrins; Biocompatible Materials; Cell Movement; Doxorubicin; Drug Delivery Syst

2018
Magnetofluorescent nanohybrid comprising polyglycerol grafted carbon dots and iron oxides: Colloidal synthesis and applications in cellular imaging and magnetically enhanced drug delivery.
    Colloids and surfaces. B, Biointerfaces, 2019, Jan-01, Volume: 173

    Topics: Animals; Antineoplastic Agents; Carbon; Cell Survival; Colloids; Drug Delivery Systems; Ferric Compo

2019
Preferential Tumor Accumulation of Polyglycerol Functionalized Nanodiamond Conjugated with Cyanine Dye Leading to Near-Infrared Fluorescence In Vivo Tumor Imaging.
    Small (Weinheim an der Bergstrasse, Germany), 2019, Volume: 15, Issue:48

    Topics: Animals; Benzothiazoles; Carbocyanines; Fluorescence; Glycerol; Green Fluorescent Proteins; HeLa Cel

2019
Bioimaging of targeting cancers using aptamer-conjugated carbon nanodots.
    Chemical communications (Cambridge, England), 2013, Jul-25, Volume: 49, Issue:58

    Topics: Animals; Carbon; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Diagnostic Imag

2013
Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.
    Journal of liposome research, 2014, Volume: 24, Issue:1

    Topics: 1,2-Dipalmitoylphosphatidylcholine; Cell Line, Tumor; Cholesterol; Drug Delivery Systems; Fluorourac

2014
Molecular imaging of aquaglycero-aquaporins: its potential for cancer characterization.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:8

    Topics: Animals; Aquaglyceroporins; Carbon Radioisotopes; Cell Line, Tumor; Glycerol; Heterografts; Humans;

2013
Measurement depth enhancement in terahertz imaging of biological tissues.
    Optics express, 2013, Sep-09, Volume: 21, Issue:18

    Topics: Animals; Ethanol; Glycerol; Image Enhancement; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells.
    Biomaterials, 2014, Volume: 35, Issue:20

    Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gl

2014
Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapy.
    Chemical communications (Cambridge, England), 2015, Jan-28, Volume: 51, Issue:8

    Topics: Administration, Cutaneous; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Glycerol; H

2015
Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.
    Nanomedicine : nanotechnology, biology, and medicine, 2015, Volume: 11, Issue:7

    Topics: Animals; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Glycerol; HT29 Cells; Humans; Hydr

2015
Polymeric assembly of hyperbranched building blocks to establish tunable nanoplatforms for lysosome acidity-responsive gene/drug co-delivery.
    Biomaterials science, 2015, Volume: 3, Issue:7

    Topics: Boronic Acids; Doxorubicin; Drug Delivery Systems; Gene Transfer Techniques; Glycerol; Humans; Hydro

2015
Star-Shaped Amphiphilic Hyperbranched Polyglycerol Conjugated with Dendritic Poly(l-lysine) for the Codelivery of Docetaxel and MMP-9 siRNA in Cancer Therapy.
    ACS applied materials & interfaces, 2016, 05-25, Volume: 8, Issue:20

    Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Glycerol; Humans; MCF-7 Cells; Neoplasms; Polyly

2016
Complex Assembly of Polymer Conjugated Mesoporous Silica Nanoparticles for Intracellular pH-Responsive Drug Delivery.
    Langmuir : the ACS journal of surfaces and colloids, 2016, 11-29, Volume: 32, Issue:47

    Topics: A549 Cells; Cross-Linking Reagents; Drug Carriers; Drug Delivery Systems; Endocytosis; Fluorescent D

2016
Carcinogenicity study of 3-monochloropropane-1,2-diol in Sprague-Dawley rats.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2008, Volume: 46, Issue:9

    Topics: alpha-Chlorohydrin; Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Female; Glycerol; Male

2008
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
    Journal of controlled release : official journal of the Controlled Release Society, 2009, Jan-05, Volume: 133, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Drug Carriers; Drug Evaluation

2009
A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.
    Pharmaceutical research, 2009, Volume: 26, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Prolife

2009
Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.
    Regulatory toxicology and pharmacology : RTP, 2009, Volume: 53, Issue:2

    Topics: alpha-Chlorohydrin; Animals; Benchmarking; Carcinogens; Dose-Response Relationship, Drug; Female; Fo

2009
Targeted cancer therapy with novel high drug-loading nanocrystals.
    Journal of pharmaceutical sciences, 2010, Volume: 99, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; C

2010
Cervical cytology tests in cancer diagnosis; glycerine technique for mailing.
    Canadian Medical Association journal, 1946, Volume: 54

    Topics: Female; Glycerol; Humans; Neoplasms; Uterine Neoplasms; Vaginal Smears

1946
Adipose triglyceride lipase contributes to cancer-associated cachexia.
    Science (New York, N.Y.), 2011, Jul-08, Volume: 333, Issue:6039

    Topics: Adipose Tissue, White; Animals; Blood Glucose; Body Mass Index; Body Weight; Cachexia; Cytokines; Fa

2011
Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states.
    Journal of internal medicine, 2012, Volume: 271, Issue:4

    Topics: Adipocytes; Adipose Tissue, White; Adult; Aged; Biomarkers; Biomarkers, Tumor; Body Mass Index; Cach

2012
Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Feb-14, Volume: 45, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Female; Glycerol; Human

2012
Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake.
    Bioconjugate chemistry, 2012, Mar-21, Volume: 23, Issue:3

    Topics: Biocompatible Materials; Cells, Cultured; Complement Activation; Erythrocytes; Glycerol; Humans; Neo

2012
Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Drug Carriers; Femal

2012
Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle.
    Journal of controlled release : official journal of the Controlled Release Society, 2012, Sep-10, Volume: 162, Issue:2

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Glycerol; Light; Liposomes; Mice; Mice, Inbred BALB C; Mic

2012
Stable synthetic bacteriochlorins for photodynamic therapy: role of dicyano peripheral groups, central metal substitution (2H, Zn, Pd), and Cremophor EL delivery.
    ChemMedChem, 2012, Volume: 7, Issue:12

    Topics: Animals; Coordination Complexes; Glycerol; HeLa Cells; Humans; Neoplasms; Palladium; Pharmaceutical

2012
Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe₃O₄ magnetic nanoparticles for targeted anticancer effects.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Jan-23, Volume: 48, Issue:1-2

    Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cell Survival; Dru

2013
[Usefulness of subarachnoid phenol-glycerin block therapy for enabling cancer patients with refractory anal pain to proceed to home-based care].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39 Suppl 1

    Topics: Aged; Anus Diseases; Female; Glycerol; Home Care Services; Humans; Male; Neoplasms; Pain, Intractabl

2012
Aquaporins.
    Current biology : CB, 2013, Jan-21, Volume: 23, Issue:2

    Topics: Animals; Aquaporins; Bacteria; Cell Membrane Permeability; Gene Knockout Techniques; Glycerol; Human

2013
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Glycerol

2002
[Esterification of fatty acids by alcohols and functional role of polar and non-polar lipids in blood flow. Double bonds of lipid fatty acids in lipoproteins].
    Klinicheskaia laboratornaia diagnostika, 2003, Issue:1

    Topics: Adolescent; Adult; Alcohols; Animals; Arteriosclerosis; Child; Cholesterol Esters; Choline; Fatty Ac

2003
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
    Cancer research, 1956, Volume: 16, Issue:10 Part 1

    Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl

1956
Lactose synthesis. IV. The synthesis of milk constituents after unilateral injection of glycerol-1,3-C14 into the pudic artery.
    The Journal of biological chemistry, 1958, Volume: 233, Issue:6

    Topics: Arteries; Carbohydrate Metabolism; Glycerol; Lactose; Milk; Neoplasms; Sarcoma

1958
Distribution of cytochrome oxidase activity in Ehrlich ascites cell particulates obtained from glycerol homogenates.
    Archives of biochemistry and biophysics, 1959, Volume: 84

    Topics: Ascites; Cytochromes; Electron Transport Complex IV; Glycerol; Neoplasms

1959
[ACTION OF GLYCEROL ON EXOPHTHALMOS].
    Bollettino d'oculistica, 1963, Volume: 42

    Topics: Edema; Exophthalmos; Glycerol; Humans; Hyperthyroidism; Neoplasms; Vascular Diseases

1963
SUGAR ANTAGONISMS IN PLANT TUMOUR CELLS INDUCED BY 2,4-DICHLOROPHENOXYACETIC ACID.
    Acta biologica Academiae Scientiarum Hungaricae, 1963, Volume: 14

    Topics: 2,4-Dichlorophenoxyacetic Acid; Antimetabolites; Arabinose; Carbohydrates; Disaccharides; Fructose;

1963
INFLUENCE OF GLYCEROL-GUAIACOL-ETHER UPON GASTRIC CHANGES AFTER X-RAY THERAPY.
    Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove, 1963, Volume: 6

    Topics: Biomedical Research; Ether; Gastric Juice; Glycerol; Guaiacol; Guaifenesin; Humans; Kymography; Neop

1963
RADIOAUTOGRAPHIC EVALUATION OF FREEZE-THAW BUFFERS USING NUCLEIC ACID- AND GLYCINE-RELATED SYNTHETIC SYSTEMS IN VITRO.
    Laboratory investigation; a journal of technical methods and pathology, 1964, Volume: 13

    Topics: Adenine; Autoradiography; Buffers; Dextrans; Dimethyl Sulfoxide; Glycerol; Glycine; In Vitro Techniq

1964
THE MEDICAL TREATMENT OF SPASTICITY.
    Proceedings of the Royal Society of Medicine, 1964, Volume: 57

    Topics: Anesthesia; Anesthesia, Spinal; Breast Neoplasms; Drug Therapy; Glycerol; Humans; Injections; Inject

1964
[POSSIBILITIES OF ANTALGIC THERAPY IN PAIN DUE TO GYNECOLOGIC CARCINOMAS].
    Annali di ostetricia e ginecologia, 1964, Volume: 86

    Topics: Carcinoma; Cordotomy; Cresols; Female; Genital Neoplasms, Female; Glycerol; Humans; Injections; Inje

1964
HISTOLOGICAL FINDINGS FOLLOWING INTRATHECAL INJECTIONS OF PHENOL SOLUTIONS FOR RELIEF OF PAIN.
    British journal of anaesthesia, 1964, Volume: 36

    Topics: Cats; Drug Therapy; Glycerol; Histology; Humans; Injections; Injections, Spinal; Meningitis; Neoplas

1964
FLUORESCENCE OF MALIGNANT TISSUE.
    Lancet (London, England), 1965, Aug-28, Volume: 2, Issue:7409

    Topics: Fluorescence; Glycerol; Histocytochemistry; Neoplasms; Pathology; Ultraviolet Rays

1965
[Comparative studies of the Papanicolaou method and Hoffmann's Giemsa-glycerin drop staining in the cytodiagnosis of cancer].
    Dermatologische Wochenschrift, 1951, Volume: 123, Issue:9

    Topics: Cytodiagnosis; Glycerol; Humans; Neoplasms; Staining and Labeling

1951
[Comparative studies of the Papanicolaou method and Hoffmann's Giemsa-glycerin drop staining in the cytodiagnosis of cancer].
    Dermatologische Wochenschrift, 1951, Volume: 123, Issue:10

    Topics: Cytodiagnosis; Glycerol; Humans; Neoplasms; Staining and Labeling

1951
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:11

    Topics: Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Blotting, Western; Cell Line

2005
Encapsulation of paclitaxel in macromolecular nanoshells.
    Biomacromolecules, 2007, Volume: 8, Issue:6

    Topics: Cell Cycle; Cell Line, Tumor; Cytoskeleton; Drug Delivery Systems; Glycerol; Humans; Macromolecular

2007
Experience with the use of frozen blood.
    Canadian Medical Association journal, 1967, Jun-10, Volume: 96, Issue:23

    Topics: Adolescent; Adult; Aged; Anemia; Blood Preservation; Blood Transfusion; Female; Freezing; Glycerol;

1967
Metabolic response of whole body and peripheral tissues to enteral nutrition in weight-losing cancer and noncancer patients.
    Gastroenterology, 1983, Volume: 85, Issue:1

    Topics: Aged; Amino Acids; Body Weight; Energy Metabolism; Enteral Nutrition; Fatty Acids, Nonesterified; Fe

1983
In vitro colony formation by cryopreserved primary human tumor cells.
    Cryobiology, 1984, Volume: 21, Issue:2

    Topics: Colony-Forming Units Assay; Cryoprotective Agents; Dimethyl Sulfoxide; Freezing; Glycerol; Humans; N

1984
Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients.
    Cancer, 1982, Sep-15, Volume: 50, Issue:6

    Topics: Adult; Aged; Carbon Radioisotopes; Female; Gluconeogenesis; Glucose; Glycerol; Humans; Kinetics; Mal

1982
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
    British journal of cancer, 1995, Volume: 71, Issue:3

    Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Drug Synergism; Fluorometry; Glycerol; Huma

1995
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization.
    Cytometry, 1994, Jun-01, Volume: 16, Issue:2

    Topics: Breast Neoplasms; Centromere; Chromatin; Chromosomes, Human; DNA Probes; DNA, Neoplasm; Formaldehyde

1994
Misdiagnosis of cancer due to multiple glove powder granulomas.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1997, Issue:579

    Topics: Absorption; Cross-Linking Reagents; Diagnosis, Differential; Epichlorohydrin; False Negative Reactio

1997
[Gene delivery into human cancer cells via transferrin receptor].
    Nihon rinsho. Japanese journal of clinical medicine, 1998, Volume: 56, Issue:3

    Topics: Adenoviridae; Biotin; DNA; Drug Delivery Systems; Genetic Therapy; Genetic Vectors; Glycerol; Humans

1998
Permeation of human ovarian tissue with cryoprotective agents in preparation for cryopreservation.
    Human reproduction (Oxford, England), 1998, Volume: 13, Issue:2

    Topics: Adult; Antineoplastic Agents; Cryopreservation; Cryoprotective Agents; Dimethyl Sulfoxide; Ethylene

1998
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:5

    Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans;

1998
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP

1998
Prospects for glycerol-rescued hypoglycemia as a cancer therapy.
    Medical hypotheses, 2001, Volume: 56, Issue:3

    Topics: Animals; Antineoplastic Agents; Gluconeogenesis; Glycerol; Humans; Hypoglycemia; Hypoglycemic Agents

2001
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Anti-cancer drugs, 2002, Volume: 13, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug;

2002
Oncornaviruslike particles in human malignancies.
    Medical microbiology and immunology, 1976, Jun-01, Volume: 162, Issue:2

    Topics: Centrifugation, Density Gradient; Female; Glycerol; Humans; Neoplasms; Oncogenic Viruses; RNA; RNA-D

1976
Anesthetic measures in management of pain associated with malignancy.
    Seminars in oncology, 1977, Volume: 4, Issue:1

    Topics: Analgesia; Anesthesia, Epidural; Autonomic Nerve Block; Carcinoma; Denervation; Ethanol; Female; Gly

1977
[Epidural administration of bupivacaine in glycerine solution can prolong analgesia].
    Ma zui xue za zhi = Anaesthesiologica Sinica, 1992, Volume: 30, Issue:1

    Topics: Adult; Analgesia, Epidural; Bupivacaine; Female; Glycerol; Humans; Injections, Epidural; Male; Middl

1992
[Neural blockage of phenol-glycerine for cancer pain].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1991, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms;

1991
Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer.
    Clinical physiology (Oxford, England), 1989, Volume: 9, Issue:5

    Topics: Aged; Blood Pressure; Cachexia; Energy Metabolism; Epinephrine; Fatty Acids, Nonesterified; Female;

1989
Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients.
    Annals of surgery, 1988, Volume: 208, Issue:5

    Topics: Aged; Body Composition; Catecholamines; Creatinine; Epinephrine; Female; Glycerol; Humans; Hydrocort

1988
Free fatty acid turnover and lipolysis in septic mechanically ventilated cancer-bearing humans.
    Metabolism: clinical and experimental, 1988, Volume: 37, Issue:7

    Topics: Adolescent; Adult; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Infectio

1988
Whole body lipid and energy metabolism in the cancer patient.
    Metabolism: clinical and experimental, 1987, Volume: 36, Issue:10

    Topics: Adult; Aged; Cachexia; Energy Metabolism; Esterification; Fatty Acids, Nonesterified; Female; Glycer

1987
[Analgesic therapy of cancer outpatients].
    Voprosy onkologii, 1987, Volume: 33, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Analgesics; Drug Evaluation; Ethanol; Glycerol; Humans; Middle Aged; N

1987
Cancer cachexia and the rate of whole body lipolysis in man.
    Metabolism: clinical and experimental, 1986, Volume: 35, Issue:4

    Topics: Adult; Aged; Cachexia; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Lipid Metabolism; Lipol

1986
[Viability and effectivness of deep cooled human bone marrow cells].
    Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1970, Volume: 51, Issue:7

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cell Co

1970
[Chemical denervation analgesia of incurable oncological patients].
    Khirurgiia, 1971, Volume: 47, Issue:8

    Topics: Adult; Aged; Analgesia; Anesthesia, Epidural; Ethanol; Female; Glycerol; Humans; Male; Middle Aged;

1971
Subarachnoid phenol nerve blocks for relief of pain in advanced malignancy.
    Canadian journal of surgery. Journal canadien de chirurgie, 1972, Volume: 15, Issue:1

    Topics: Adult; Aged; Autonomic Nerve Block; Colonic Neoplasms; Female; Genital Neoplasms, Female; Glycerol;

1972
Regulatory defect of glycolysis in human lipoma.
    British medical journal, 1974, Jan-19, Volume: 1, Issue:5898

    Topics: Adipose Tissue; Citrates; Feedback; Glucose; Glucosephosphates; Glycerides; Glycerol; Glycolysis; Hu

1974
Intrathecal phenol for cancer pain.
    Acta anaesthesiologica Scandinavica, 1972, Volume: 16, Issue:1

    Topics: Fecal Incontinence; Glycerol; Headache; Humans; Injections, Spinal; Methods; Motor Neurons; Muscles;

1972
A simple radiochemical assay of inhibition by chemotherapeutic agents of precursor incorporation into biopsy samples, effusions, and leukocyte preparations.
    Cancer research, 1968, Volume: 28, Issue:11

    Topics: Amino Acids; Animals; Antineoplastic Agents; Biological Assay; Biopsy; Carbon Isotopes; Carcinoma, E

1968
Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues.
    Cancer research, 1969, Volume: 29, Issue:1

    Topics: Adolescent; Alkenes; Chromatography, Thin Layer; Ethers; Glycerol; Humans; Lipids; Male; Neoplasms

1969
[HTO-formation from tritium labelled compounds in vivo as proof of tritium incorporation].
    Arzneimittel-Forschung, 1969, Volume: 19, Issue:4

    Topics: Animals; Ascites; Estradiol; Female; Glycerol; Glycosuria; Hydrocortisone; Lactates; Neoplasms; Preg

1969
What to expect in 2018: science in the new year.
    Nature, 2018, 01-04, Volume: 553, Issue:7686

    Topics: Astronauts; Astronomy; Climate Change; Clinical Trials as Topic; DNA, Ancient; Drug Resistance, Micr

2018
Cancer, climate, plastics: why 'earthshots' are harder than moonshots.
    Nature, 2019, Volume: 571, Issue:7764

    Topics: Anti-Bacterial Agents; Biomedical Research; Cooperative Behavior; Environmental Pollution; Global Wa

2019
Multi-scale clustering by building a robust and self correcting ultrametric topology on data points.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Autistic Disorder; Behavior, Animal; Cluster Analysis; Computational Biology; Gene Expressi

2013